OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
November 29, 2022
The decision to move forward in Phase III development stems from the threat of resistance to current malaria treatment growth.
May 15, 2022
The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.
May 04, 2022
The two companies signed an exclusive collaboration agreement for the Aidaptus auto-injector.
October 12, 2021
AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.
July 03, 2021
Bi-layer tablets are an under-utilized option that can be employed to help reduce treatment burden, but their formulation is more complex than for conventional monolayer products.
September 23, 2019
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of AstraZeneca’s Qtrilmet (metformin hydrochloride, saxagliptin, and dapagliflozin) modified-release tablets for treating type-2 diabetes.
August 02, 2019
A design strategy can ensure conflicting properties are managed appropriately for multi-API controlled-release formulations.
May 15, 2019
Empty and prefilled syringes must pass a range of quality control tests.
December 02, 2018
Using training devices may ease patient anxiety about using autoinjectors and prefilled syringes, potentially leading to improved patient adherence.
FDA Commissioner Scott Gottlieb has been promoting drug market competition in recent months that includes new guidance documents and targeted advisories to support R&D of complex drugs and combination products.